Related Experiment Videos
Low plasma cyclic nucleotides in multiple sclerosis
1Athens University Medical School, Eginition Hospital, Greece.
European Neurology
|January 1, 1988
Abstract:
The concentrations of cyclic AMP and cyclic GMP were estimated in plasma of 26 patients with definite multiple sclerosis (MS) in relapse, and compared to that of 26 sex- and age-matched healthy controls. MS patients had significantly lower levels of both nucleotides. The levels of c-GMP correlated negatively to the Disability Status Scale score.
Insights
Multiple sclerosis patients in relapse show lower cyclic AMP and cyclic GMP plasma levels compared to healthy individuals. Cyclic GMP levels correlated with disability, suggesting a role in multiple sclerosis progression.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Alterations in intracellular signaling molecules like cyclic nucleotides may play a role in MS pathogenesis.
Purpose of the Study:
- To investigate plasma concentrations of cyclic AMP (cAMP) and cyclic GMP (cGMP) in patients with active multiple sclerosis.
- To explore the relationship between these nucleotide levels and clinical disability in MS patients.
Main Methods:
- Plasma samples were collected from 26 patients with definite multiple sclerosis in relapse.
- Plasma samples were also collected from 26 age- and sex-matched healthy controls.
- Concentrations of cAMP and cGMP were measured using established biochemical assays.
Main Results:
- Patients with multiple sclerosis exhibited significantly lower plasma levels of both cAMP and cGMP compared to healthy controls.
- A negative correlation was observed between cyclic GMP levels and the Disability Status Scale score in MS patients.
Conclusions:
- Reduced plasma levels of cAMP and cGMP may be associated with active multiple sclerosis.
- Cyclic GMP levels might serve as a potential biomarker for disease severity or progression in multiple sclerosis.